Zhang Hongzhi, Jiang Huijuan, Hu Xigang, Jia Zongling
Department of Radiotherapy, Huaihe Hospital of Henan University, Kaifeng 475000, Henan, China.
J Cancer Res Ther. 2015 Aug;11 Suppl 1:C118-21. doi: 10.4103/0973-1482.163864.
The purpose of this meta-analysis was to assess the clinical efficacy and side effects of Aidi injection combined with radiation in the treatment of non-small cell lung cancer (NSCLC).
By searching PubMed, the Cochrane central register of controlled trials, EMBSE and CNKI databases, the efficacy and side effect data of Aidi injection combined with radiation in the treatment of NSCLC from the published clinical studies were collected. The data were pooled using Stata version 11.0 software (http://www.stata.com; Stata Corporation, College Station, TX).
Ten clinical studies with 1084 subjects were included in this meta-analysis. The combined data showed the clinical efficacy in experiment group was higher than that of control group (risk ratio [RR] = 1.72, 95% confidence interval [CI]: 1.52-1.96, P = 0.00); four articles reported the life quality improvement. The pooled data showed that the use of Aidi can significantly improve the quality of life in the procedure of radiation (RR = 2.29, 95% CI: 1.76-2.98, P = 0.00); six studies reported the radiation toxicities. The pooled data showed that Aidi injection can significant decrease the radiation pneumonia (OR = 0.46, 95% CI: 0. 34-0.63), radiation esophagitis (OR = 0.53, 95% CI: 0.40-0.71), and marrow suppression (OR = 0.50, 95% CI: 0.42-0.59).
Aidi injection can improve the clinical efficacy, quality of life, and decrease the radiation-related toxicities in NSCLC patients who received radiation.
本荟萃分析旨在评估艾迪注射液联合放疗治疗非小细胞肺癌（NSCLC）的临床疗效及副作用。
通过检索PubMed、Cochrane对照试验中心注册库、EMBSE和中国知网数据库，收集已发表临床研究中艾迪注射液联合放疗治疗NSCLC的疗效及副作用数据。使用Stata 11.0软件（http://www.stata.com；Stata公司，德克萨斯州大学城）对数据进行汇总。
本荟萃分析纳入了10项临床研究，共1084名受试者。合并数据显示，试验组的临床疗效高于对照组（风险比[RR]=1.72，95%置信区间[CI]：1.52 - 1.96，P = 0.00）；4篇文章报道了生活质量改善情况。汇总数据显示，使用艾迪可在放疗过程中显著提高生活质量（RR = 2.29，95% CI：1.76 - 2.98，P = 0.00）；6项研究报道了放疗毒性。汇总数据显示，艾迪注射液可显著降低放射性肺炎（OR = 0.46，95% CI：0.34 - 0.63）、放射性食管炎（OR = 0.53，95% CI：0.40 - 0.71）和骨髓抑制（OR = 0.50，95% CI：0.42 - 0.59）的发生率。
艾迪注射液可提高接受放疗的NSCLC患者的临床疗效、生活质量，并降低放疗相关毒性。
